<DOC>
	<DOCNO>NCT01861938</DOCNO>
	<brief_summary>This study base hypothesis stimulation immune response tumor help destroy residual tumor melanoma patient high risk disease recurrence patient relatively low tumor burden already get first line treatment disease . Ongoing clinical trial Hadassah Hospital show vaccination patient cell line tumor cell patient , combination three cell line partially match patient 's cell characteristic , could improve immune response tumor , associate improved disease-free overall survival . In study , investigator evaluate efficacy modify tumor cell vaccine , term immune response , improve disease-free overall survival . The vaccine consist cell line high expression level melanoma molecule , genetically modify induce strong immune response .</brief_summary>
	<brief_title>Modified Melanoma Vaccine High Risk Low Residual Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Patients include protocol must carry one follow tissue type allele : HLAA2 , A24 , A33 , B35 , B49 , CW04/12 ( 04/08 ) . We estimate 50 % melanoma patient eligible . 2 . Cutaneous malignant melanoma AJCC stage IIb ( 4 mm ) IIc ( ulcerated melanoma 4mm ) . 3 . Metastatic melanoma AJCC stage III ( nodal involvement , N13a , b ) post surgical removal lymph node . 4 . Metastatic melanoma AJCC stage IV , completely resect . 5 . Non cutaneous malignant melanoma respective stage include uveal mucosal melanoma . 6 . Melanoma either mutant wildtype BRAF . 7 . Karnofsky performance status 80 ( Normal activity effort ) . 8 . No active cardiorespiratory disease . 9 . Hematocrit 25 % WBC 3000 . 10 . Informed consent patient . 1 . Administration cytotoxic drug extensive radiotherapy le 28 day prior protocol administration . 2 . Active brain metastasis require corticosteroid . 3 . Concurrent malignancy ( skin cancer , carcinoma situ cervix early stage prostate cancer ) . 4 . Active serious infection . 5 . Allergy penicillin . 6 . Patient 's wish withdraw study stage .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>melanoma</keyword>
	<keyword>vaccine</keyword>
	<keyword>Resectable AJCC stage IV</keyword>
	<keyword>AJCC stag IIb-c , III</keyword>
	<keyword>Patients low-burden</keyword>
	<keyword>fail</keyword>
	<keyword>respond</keyword>
	<keyword>one treatment line</keyword>
</DOC>